Mpox diagnostics: access begins with the specimen-to-result pathway.
A test can be technically capable and still fail to improve outbreak intelligence if the wrong specimen is collected, transport is delayed, controls are weak, referral rules are unclear or results cannot reach authorised response teams. Diagnostic access is therefore a system property.
WHO’s 31 July 2026 situation report recorded 1,128 confirmed mpox cases and nine deaths reported by 33 countries in June. The African Region accounted for 722 of those cases. For the six weeks ending 19 July, ten African countries reported active transmission, with 1,112 confirmed cases and 12 deaths. WHO cautions that delayed reporting, reduced surveillance and competing response demands can lead to retrospective changes and underestimation.
The epidemiology is wider than any single testing model
The same WHO report describes continued circulation of all monkeypox virus clades. Costa Rica, Ghana and Lithuania reported clade Ib for the first time, while local clade Ib transmission had been reported in several European countries and Thailand. Madagascar reported the largest active outbreak in the African Region, including 940 confirmed cases during the six-week reporting window.
These observations do not support a one-size-fits-all laboratory design. Testing demand, specimen transport time, instrument placement, referral capacity and the need for clade characterization will differ between a national reference laboratory, a provincial laboratory, a near-patient site and a border-area response.
What WHO says about the diagnostic method
WHO’s current interim guidance, published 12 November 2024, places nucleic acid amplification testing at the centre of mpox confirmation. It discusses near-patient molecular options as part of decentralisation strategies where the evidence and operating context support them. The same guidance maintains its recommendation against using antigen rapid diagnostic tests for mpox diagnosis based on the evidence reviewed.
WHO also highlights the need to reduce the risk of gene-target failure and to differentiate viral clades where relevant. This makes assay governance an ongoing responsibility: laboratories need defined review triggers for target coverage, controls, discordant results and referral for sequencing or confirmatory testing.
The specimen-to-result pathway
Vision interpretation: the practical unit of diagnostic readiness is not the box of reagents. It is the controlled path that connects an eligible person, an appropriate specimen and an authorised result.
- Case and test eligibility: national algorithms should define who is tested, by which method and at which level of the laboratory network.
- Specimen quality: collection, labelling, packaging and acceptance criteria should be trained and documented before surge demand begins.
- Transport and referral: turnaround targets should include the time before and after amplification, not only instrument run time.
- Quality controls: positive, negative and internal controls, contamination controls and invalid-result rules should be explicit.
- Result governance: reporting, escalation, confirmatory testing and data protection should follow authorised public-health pathways.
- Continuity: extraction materials, consumables, cold-chain capacity, maintenance and replacement components should be planned as one supply system.
Decentralisation must carry quality with it
Moving testing closer to affected communities may reduce transport time and improve access. It can also multiply points of failure if new sites are introduced without competency assessment, equipment verification, environmental controls, external oversight, secure reporting and reliable referral links.
WHO reported that, as of 22 July 2026, it was coordinating a multi-country study of point-of-care mpox tests in Belgium, the Democratic Republic of the Congo, Ghana and Madagascar. That evaluation activity is important context: decentralisation should be built around demonstrated performance and defined use conditions, not assumed equivalence between formats.
Quality-assured access and local capacity
As of 22 July 2026, WHO reported that 73 manufacturers had requested information about Emergency Use Listing for MPXV nucleic acid amplification tests. Sixteen dossiers from 14 manufacturers had been submitted, and 12 products were listed for emergency use.
Vision interpretation: procurement, technology transfer and local manufacturing should preserve the evidence, documentation and controls on which quality-assured access depends. Localisation is most useful when it creates durable capability: trained people, traceable materials, controlled production, lot-release testing, stability oversight, regulatory alignment and dependable service support.
Local production does not replace independent evaluation or national authorisation. Nor does a WHO Emergency Use Listing automatically establish suitability for every laboratory or country. Product selection and implementation remain decisions for the responsible authorities within the applicable regulatory and public-health framework.
The Vision Biotechnology response lens
Vision Biotechnology supports qualified partners in designing controlled molecular workflows and local diagnostic capacity. A responsible mpox-readiness programme may include laboratory-network mapping, workflow and equipment planning, extraction and PCR implementation support, operator training, quality-control design, supply continuity planning and structured technology transfer.
Any product-specific performance statement must remain tied to its validated scope, specimen type, instructions for use and regulatory status. Suspected cases and results should be managed only through authorised clinical and public-health channels.
Map the complete path before increasing test volume: who collects, what specimen is accepted, where testing occurs, how quality is demonstrated, when a result is repeated or referred, and how supplies are sustained. Faster amplification is valuable only when the surrounding system is ready.
Primary sources
This article separates WHO-reported information from Vision Biotechnology interpretation. It provides general laboratory-readiness information and does not constitute medical advice, a diagnostic recommendation, regulatory approval or a claim about any specific Vision product.